ArticleJournal of human genetics2026
FRAXE-associated intellectual disability: clinical and molecular insights into an underdiagnosed condition.
Article in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FRAXE-associated intellectual developmental disorder (FRAXE-ID) is a rare X-linked condition resulting from disruption of the AFF2 gene, usually through expansion of more than 200 CCG repeats and subsequent hypermethylation. Despite an estimated incidence of 1 in 50,000 to 100,000 males, it remains underdiagnosed due to its variable and non-specific phenotype. This report presents the clinical and molecular findings of three unrelated young male patients diagnosed with FRAXE-ID. All exhibited global developmental delay, mild to moderate intellectual disability, and subtle dysmorphic features. Molecular testing confirmed full mutations in the AFF2 gene in all cases, with one patient demonstrating size mosaicism. Southern blot confirmed hypermethylation of expanded alleles. The mothers of all three patients were premutation carriers. These findings emphasize the non-syndromic and often overlooked nature of FRAXE-ID. Accurate diagnosis relies on specific molecular techniques, underscoring the importance of clinical awareness and targeted testing to ensure appropriate diagnosis, management, and genetic counselling.
Indexed as
Identifiers
41087597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.